Ovarian Serous Cystadenocarcinoma: Correlation between gene mutation status and selected clinical features

Overview

Introduction

This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.

Summary

Testing the association between mutation status of 57 genes and 4 clinical features across 316 patients, no significant finding detected with Q value < 0.25.

No gene mutations related to clinical features.

Results

Overview of the results

Table 1. Get Full Table Overview of the association between mutation status of 57 genes and 4 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, no significant finding detected.


		Clinical Features	Time to Death	AGE	KARNOFSKY PERFORMANCE SCORE	NEOADJUVANT THERAPY
	nMutated (%)	nWild-Type	logrank test	t-test	t-test	Fisher's exact test
TP53	276 (87%)	40	0.389 (1.00)	0.649 (1.00)	0.585 (1.00)	0.505 (1.00)
BRCA1	12 (4%)	304	0.957 (1.00)	0.65 (1.00)		1 (1.00)
RB1	9 (3%)	307	0.241 (1.00)	0.204 (1.00)		0.658 (1.00)
CSMD3	18 (6%)	298	0.262 (1.00)	0.61 (1.00)	0.285 (1.00)	0.53 (1.00)
NF1	14 (4%)	302	0.2 (1.00)	0.606 (1.00)		0.478 (1.00)
FAT3	19 (6%)	297	0.139 (1.00)	0.743 (1.00)	0.643 (1.00)	0.215 (1.00)
CYP11B1	7 (2%)	309	0.0926 (1.00)	0.793 (1.00)		0.104 (1.00)
CHST2	5 (2%)	311	0.851 (1.00)	0.0727 (1.00)		1 (1.00)
C9ORF171	5 (2%)	311	0.895 (1.00)	0.121 (1.00)	0.746 (1.00)	0.591 (1.00)
DUSP19	4 (1%)	312	0.785 (1.00)	0.593 (1.00)		0.536 (1.00)
GABRA6	6 (2%)	310	0.815 (1.00)	0.0121 (1.00)		0.595 (1.00)
TACC3	5 (2%)	311	0.0969 (1.00)	0.626 (1.00)		0.591 (1.00)
CDK12	9 (3%)	307	0.367 (1.00)	0.214 (1.00)	0.0171 (1.00)	0.193 (1.00)
EPHA7	7 (2%)	309	0.309 (1.00)	0.404 (1.00)		0.61 (1.00)
PPP1R3A	8 (3%)	308	0.539 (1.00)	0.0819 (1.00)		0.632 (1.00)
USH2A	20 (6%)	296	0.338 (1.00)	0.835 (1.00)	0.0171 (1.00)	0.761 (1.00)
GLI2	9 (3%)	307	0.133 (1.00)	0.0829 (1.00)		0.00971 (1.00)
BRCA2	11 (3%)	305	0.085 (1.00)	0.372 (1.00)		1 (1.00)
FAM171B	7 (2%)	309	0.61 (1.00)	0.388 (1.00)		1 (1.00)
ZNF479	5 (2%)	311	0.539 (1.00)	0.872 (1.00)		1 (1.00)
SI	10 (3%)	306	0.646 (1.00)	0.219 (1.00)		0.22 (1.00)
C6ORF142	5 (2%)	311	0.258 (1.00)	0.147 (1.00)		0.591 (1.00)
SLCO1C1	6 (2%)	310	0.741 (1.00)	0.774 (1.00)		0.595 (1.00)
GAS2L1	4 (1%)	312	0.178 (1.00)	0.056 (1.00)		0.141 (1.00)
C1ORF95	3 (1%)	313	0.72 (1.00)	0.956 (1.00)		1 (1.00)
KCNJ12	5 (2%)	311	0.688 (1.00)	0.643 (1.00)		0.591 (1.00)
QSOX2	5 (2%)	311	0.835 (1.00)	0.8 (1.00)		1 (1.00)
TBP	4 (1%)	312	0.323 (1.00)	0.191 (1.00)		0.141 (1.00)
ACBD4	3 (1%)	313	0.811 (1.00)	0.182 (1.00)		1 (1.00)
C10ORF113	3 (1%)	313	0.0628 (1.00)	0.83 (1.00)		1 (1.00)
GPR149	6 (2%)	310	0.594 (1.00)	0.166 (1.00)		1 (1.00)
PAOX	4 (1%)	312	0.446 (1.00)	0.957 (1.00)		0.536 (1.00)
PXN	5 (2%)	311	0.238 (1.00)	0.731 (1.00)		1 (1.00)
SNTG1	5 (2%)	311	0.401 (1.00)	0.417 (1.00)		0.591 (1.00)
EFEMP1	5 (2%)	311	0.61 (1.00)	0.0549 (1.00)		0.591 (1.00)
VN1R5	4 (1%)	312	0.598 (1.00)	0.805 (1.00)		0.141 (1.00)
MOGAT3	4 (1%)	312	0.271 (1.00)	0.905 (1.00)		1 (1.00)
TMEM132D	7 (2%)	309	0.343 (1.00)	0.784 (1.00)	0.734 (1.00)	0.0193 (1.00)
ARHGEF9	5 (2%)	311	0.0717 (1.00)	0.428 (1.00)		1 (1.00)
HIST1H1C	4 (1%)	312	0.0793 (1.00)	0.888 (1.00)		1 (1.00)
TOP2A	6 (2%)	310	0.674 (1.00)	0.0743 (1.00)		0.0678 (1.00)
ATP6AP1	4 (1%)	312	0.699 (1.00)	0.273 (1.00)		1 (1.00)
DEFB118	3 (1%)	313	0.452 (1.00)	0.216 (1.00)		1 (1.00)
HAS2	5 (2%)	311	0.74 (1.00)	0.19 (1.00)		0.591 (1.00)
LZTS2	4 (1%)	312	0.0181 (1.00)	0.189 (1.00)		0.536 (1.00)
PXDNL	7 (2%)	309	0.118 (1.00)	0.433 (1.00)		0.61 (1.00)
RASAL1	6 (2%)	310	0.991 (1.00)	0.854 (1.00)		0.281 (1.00)
C10ORF140	5 (2%)	311	0.916 (1.00)	0.502 (1.00)		1 (1.00)
CLEC4F	5 (2%)	311	0.223 (1.00)	0.622 (1.00)		1 (1.00)
GPX6	3 (1%)	313	0.707 (1.00)	0.68 (1.00)		1 (1.00)
KIT	7 (2%)	309	0.371 (1.00)	0.0377 (1.00)		0.61 (1.00)
POTED	4 (1%)	312	0.184 (1.00)	0.537 (1.00)		0.536 (1.00)
SDC1	4 (1%)	312	0.71 (1.00)	0.833 (1.00)		1 (1.00)
SON	8 (3%)	308	0.484 (1.00)	0.0361 (1.00)		1 (1.00)
VSIG2	4 (1%)	312	0.611 (1.00)	0.787 (1.00)		0.536 (1.00)
PAX3	5 (2%)	311	0.997 (1.00)	0.949 (1.00)		0.591 (1.00)
SCEL	5 (2%)	311	0.795 (1.00)	0.478 (1.00)		1 (1.00)

Methods & Data

Input

Mutation data file = OV.mutsig.cluster.txt
Clinical data file = OV.clin.merged.picked.txt
Number of patients = 316
Number of significantly mutated genes = 57
Number of selected clinical features = 4
Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. Location of data archives could not be determined.

References

[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)

[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)

[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)

[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)